The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes
the Young Elite Scientists Sponsorship Program by CAST (No
CrossRef MicroRNAs in the Regulation of NADPH Oxidases in Vascular Diabetic and Ischemic Pathologies: A Case for Alternate Inhibitory Strategies
In my experience, many patients tolerate these symptoms better with gradual dose escalation and by taking the medication as directedon an empty stomach with water and waiting 30 minutes before eating or drinking anything else. Efficacy of semaglutide tablets The big question is: Does it work
[DOI] [PMC free article] [PubMed] [Google Scholar] 146
ACS Omega 10 (23), 2401824029
